US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Calidi Biotherapeutics, Inc. Common Stock (NY:CLDI)

1.080 UNCHANGED
Official Closing Price Updated: 8:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Calidi Biotherapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Blood Samples Could Be Used to Find Cancer-Specific Proteins Needed for Immunotherapy
Via Investor Brand Network
2 Billion Pounds of Cancer-Causing Chemicals Found Their Way into America in 2020
Via Investor Brand Network
Why Treating Cancer is So Complicated
Via Investor Brand Network
Pancreatic Cancer Exploits Wound-Healing Mechanism to Evade Immune System
Via Investor Brand Network
Systemic Challenges in US Health Care Push Cancer Patients to Fly to China
Via Investor Brand Network
Biomarkers Could Predict Patients’ Response to Bladder Cancer Therapy
Via Investor Brand Network
Administering Immunotherapy Prior to Surgery Improves Brain Cancer Treatment Outcomes
Via Investor Brand Network
Boosting Thymus Health Could Improve Treatment Outcomes in Lung Cancer
Via Investor Brand Network
Personalized mRNA Vaccine Prevents Melanoma Recurrence, New Study Finds
Via Investor Brand Network
Mathematical Study Offers Possible Fix to Melanoma Therapy Mystery
Via Investor Brand Network
Little-Known Immune Cells Bolster Anticancer Fight, Study Finds
Via Investor Brand Network
Liquid Biopsy Forecasts Response to Immunotherapy in Lung Cancer Patients
Via Investor Brand Network
Existing Immune Protein May Boost Immunotherapy Against Cancer
Via Investor Brand Network
Researchers Plan to Investigate Role of Autoantibodies in Cancer Risk, Immune Response
Via Investor Brand Network
Dietary Fat Balance Could Influence Immune System Function, Study Finds
Via Investor Brand Network
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
Top movers in Monday's after hours session ↗
Via Chartmill
Study Links Gut Microbial Metabolites to Enhanced Cancer Immunotherapy Sensitivity
Via Investor Brand Network
Understanding Why Treatment Resistance Exists in Many Cancers
Via Investor Brand Network
AI Tool Predicts the Optimal Presurgical Treatments for Breast Cancer
Via Investor Brand Network
Topics Artificial Intelligence
Comprehensive Review Shows Gut Microbiome Influences Immunotherapy Efficacy
Via Investor Brand Network
Currently Approved Drug Could Boost Immunotherapy Against Liver Cancer
Via Investor Brand Network
Why Men Need Sexual Health Help While Undergoing Cancer Treatment
Via Investor Brand Network
FIU Researchers Discover New Way of Extending Immune Cell Lifespan and Effectiveness
Via Investor Brand Network
News headline image
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9
Via ACCESS Newswire
New Pill Offers Hope Against Pancreatic Cancer
Via Investor Brand Network
New Inhalable Agent Could Improve Treatment Outcomes in Lung Cancer
Via Investor Brand Network
Scientists Inch Closer to Developing a Lung Cancer Blood Test
Via Investor Brand Network
Researchers Create Less Toxic, More Effective Immunotherapy Against Blood Cancer
Via Investor Brand Network
NHS Starts Offering Immunotherapy Injection to Cancer Patients
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >